Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.58 |
| ▸ | FNTA | P49354 | 16/20 | 0.53 |
| ▸ | FNTB | P49356 | 16/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 13/20 | 0.53 |
| ▸ | NRAS | P01111 | 1/20 | 0.50 |
| ▸ | HRAS | P01112 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052448 | 0.83 | CYP11B1 (0.49) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7050806 | 0.83 | FNTA (0.61) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL8487144 | 0.77 | PRKAA2 (0.53) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7743501 | 0.76 | FNTA (0.54) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7743768 | 0.75 | FNTA (0.66) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7086608 | 0.74 | CYP11B1 (0.79) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7738189 | 0.74 | FNTA (0.64) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3824590 | 0.74 | CYP11B1 (1.00) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7665146 | 0.74 | FNTA (0.73) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7047853 | 0.73 | FNTA (0.64) | FNTAFNTBPGGT1BNRASHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216441-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216441-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | CYP11B1 151/4885CYP11B2 221/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.